ReShape Lifesciences Inc

Research ReShape Lifesciences Inc (HIND) on Bullrun: market cap USD 14.95M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerHIND
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 14.95M
• Financial periodFY2025
• RevenueUSD 319.71K
• Revenue growth-96.0%
• Net income-USD 10.26M
• Gross margin68.4%

Valuation Snapshot

latest market cap is USD 14.95M.

About ReShape Lifesciences Inc

Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments. The company's lead product candidate VT-1953, a dual DNA Gyrase/Topoisomerase inhibitor and immunomodulator in a topical gel formulation that is in phase 2 clinical stage for the treatment of bacterial conjunctivitis.

Frequently asked questions

What is ReShape Lifesciences Inc's market cap?

ReShape Lifesciences Inc's market capitalization is USD 14.95M.

What does ReShape Lifesciences Inc do?

Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments.